Cipla saw the highest growth of 0.99% in patent filings in June and 0.49% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and grants by 0.49%. GlobalData’s DataBook provides a comprehensive analysis of Cipla‘s patent filings and grants. Buy the databook here.
Cipla has been focused on protecting inventions in World Intellectual Property Organization(WIPO) with four publications in Q2 2024
The World Intellectual Property Organization(WIPO) Patent Office dominates the patent filings with nearly 67% of filings. The World Intellectual Property Organization(WIPO), European Patent Office(EPO), United States(US), and Australia(AU) patent Office are among the top ten patent offices where Cipla is filings its patents. Among the top granted patent authorities, Cipla has 33% of its grants in Australia(AU) and 33% in Canada(CA).
Roche could be the strongest competitor for Cipla
Medical test kits related patents lead Cipla portfolio followed by packaging, and multiple sclerosis
Cipla has highest number of patents in medical test kits followed by packaging, multiple sclerosis, secondary progressive multiple sclerosis (spms), and psychosis.
For comprehensive analysis of Cipla's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.